Skip to main content

Main menu

  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us

Future Healthcare Journal

  • FHJ Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About FHJ
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

User menu

  • Log in

Search

  • Advanced search
RCP Journals
Home
  • Log in
  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us
Advanced

Future Healthcare Journal

futurehosp Logo
  • FHJ Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About FHJ
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

Lessons learned from an audit of the use of atorvastatin 80 mg for secondary prevention of cardiovascular disease in a tertiary hospital

Khoon-Sheng Kok and Timothy Gilbert
Download PDF
DOI: https://doi.org/10.7861/futurehosp.3-2-s10
Future Healthcare Journal June 2016
Khoon-Sheng Kok
Norfolk and Norwich University Hospital, Norwich, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Timothy Gilbert
Norfolk and Norwich University Hospital, Norwich, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Aims

  • To determine if all patients admitted with acute coronary syndrome (ACS) are initiated on atorvastatin 80 mg (Atorva80) ‘without delay’ as per NICE guidance issued in July 2014, unless contraindicated or a documented consultant decision.

  • To determine if the above applied to patients already on a different statin therapy.

  • To determine if patients had their liver function tests (LFTs) checked prior to initiating on Atorva80.

Methods

This was a prospective audit of consecutive patients that attended the hospital with an acute admission of ACS. Their drug charts and blood results were reviewed within 48 hours and upon discharge. Patients’ demographics, clinical information and statin usage were recorded and analysed.

Results

40 patients admitted with ACS were reviewed in a 3-week period. Their mean age was 67.5 years old, with majority of patients being male (n = 33).

26 patients were statin naive on arrival to hospital. Out of these patients, only 53.8% (n = 14) were started on Atorva80. The other 12 patients were put on various types of statins, with five patients placed on simvastatin 40 mg. Only one patient had a documented consultant decision for not initiating Atorva80. 23 out of 26 statin-naive patients had LFTs checked prior to appropriate commencement.

14 patients were already on a lipid-lowering agent on admission, with one patient on bezafibrate and one on Atorva80. Excluding these patients, 50% (n = 6) of patients did not have their statins increased or changed to Atorva80 after ACS.

Patients not placed on Atorva80 had no pharmacological contraindications for this.

When we reviewed patients’ medications on discharge, five patients had changed to Atorva80 appropriately.

Conclusions

Our audit highlights poor compliance towards NICE guidance in the use of Atorva80 for secondary prevention of cardiovascular disease in our trust. One of the reasons could be due to lack of knowledge from juniors, as evident by change to appropriate medication on discharge upon senior review. We plan to carry out teaching sessions to juniors at the start of their cardiology rotation, with a reaudit planned in a year's time.

Nonetheless, we need to be cautious in following NICE guidance strictly. Switching to high-dose statins needs to be considered on a case-by-case basis. The audit highlights need for further guidance in patients who develop ACS already on a lipid-lowering agent, and whether a change in type and/or dosage of statin is necessary.

  • © Royal College of Physicians 2016. All rights reserved.
Back to top
Previous articleNext article

Article Tools

Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Lessons learned from an audit of the use of atorvastatin 80 mg for secondary prevention of cardiovascular disease in a tertiary hospital
Khoon-Sheng Kok, Timothy Gilbert
Future Healthcare Journal Jun 2016, 3 (Suppl 2) s10; DOI: 10.7861/futurehosp.3-2-s10

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Lessons learned from an audit of the use of atorvastatin 80 mg for secondary prevention of cardiovascular disease in a tertiary hospital
Khoon-Sheng Kok, Timothy Gilbert
Future Healthcare Journal Jun 2016, 3 (Suppl 2) s10; DOI: 10.7861/futurehosp.3-2-s10
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Aims
    • Methods
    • Results
    • Conclusions
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Obtaining an ‘informed’ consent for primary percutaneous coronary intervention (PPCI) in non-English speaking patients…the dilemma
  • Learning from mistakes: a review of clinical incidents occurring at Royal Surrey County Hospital and how we can learn from these to improve patient outcomes
  • Characteristics of patients with chronic obstructive pulmonary disease (COPD) admitted to a tertiary referral hospital
Show more HEALTH SERVICE AND POLICY

Similar Articles

Navigate this Journal

  • Journal Home
  • Current Issue
  • Ahead of Print
  • Archive

Related Links

  • ClinMed - Home
  • FHJ - Home

Other Services

  • Advertising
futurehosp Footer Logo
  • Home
  • Journals
  • Contact us
  • Advertise
HighWire Press, Inc.

Follow Us:

  • Follow HighWire Origins on Twitter
  • Visit HighWire Origins on Facebook

Copyright © 2021 by the Royal College of Physicians